Transdermal square-wave testosterone therapy: mCRPC

Buy Lab Tests Online

madman

Super Moderator
Transdermal square-wave testosterone therapy: A pilot trial in metastatic castration-resistant prostate cancer (2023)
Nellowe Candelario, Andrew Nicklawsky, Laura Graham, Elaine T. Lam, Eryn Callihan, Michael Wacker, Thomas W. Flaig, Elizabeth R Kessler; the University of Colorado Cancer Center Anschutz Medical Campus, Aurora, CO


Background

Metastatic castration-resistant prostate cancer (mCRPC) becomes resistant to antiandrogen therapies due to a variety of adaptive mechanisms. Intramuscular bipolar androgen therapy (BAT) which alternates between high and low testosterone (T) levels is therapeutically active in mCRPC and confers sensitivity to second-generation androgen receptor antagonists such as enzalutamide (ENZA). We hypothesized that transdermal T with sustained supraphysiologic T levels would lead to high response rates to ENZA in mCRPC. We also hypothesized Square-wave transdermal T therapy would be a safe alternative to BAT due to the ability to quickly withdraw therapy in the setting of symptoms.


Methods

This was an open-label, single-site, phase 2 feasibility trial in men with asymptomatic mCRPC who had not previously received ENZA. Transdermal T was administered at a dose of 100 mg/day for a minimum of 12 weeks and until disease progression. Therapy was then switched to ENZA 160 mg/day until the next disease progression. Patients who initially responded to T could receive a second course of transdermal T followed by ENZA, remaining on study until progression on both T and ENZA or for the 12-month study duration, whichever was sooner. ADT was continued throughout. The primary endpoint of the study was feasibility. T dose was adjusted to achieve T levels between 900-1500 ng/dL. Secondary endpoints included PSA50 response rate (50% decline in PSA) and safety.


Result

Fifteen patients were enrolled. Ten (66.7%) had Gleason .8 disease. Thirteen (86.7%) patients had bone metastases. The median baseline PSA was 11.73 ng/mL. The primary endpoint of feasibility based on patient recruitment and retention was met. The median testosterone level on T was 901.3 ng/dL (Range: 645.2 to 1171.1). Median time on therapy was 15.9 weeks on T and 25.9 weeks on ENZA. PSA50 was 13.3% on initial T therapy and 66.7% after switching to ENZA. Three (20%) patients did not initiate ENZA after T progression. Two desired to avoid androgen-related side effects and 1 initiated chemotherapy. No Grade 3 or higher adverse events (AEs) occurred on T and the most common AEs were weight gain, rash, and nipple sensitivity.


Conclusions

Square-wave transdermal T alternating with ENZA is feasible and achieves adequate T levels in the treatment of asymptomatic mCRPC. Given the acceptable safety profile and quick reversibility, transdermal T warrants further exploration, and we have expanded enrollment to include higher-risk patient populations.
 

Attachments

  • jco.2023.41.6_suppl.188.pdf
    33 KB · Views: 20
Defy Medical TRT clinic doctor

madman

Super Moderator
 

madman

Super Moderator
 
Buy Lab Tests Online
Defy Medical TRT clinic

Sponsors

enclomiphene
nelson vergel coaching for men
Discounted Labs
TRT in UK Balance my hormones
Testosterone books nelson vergel
Register on ExcelMale.com
Trimix HCG Offer Excelmale
Thumos USA men's mentoring and coaching
Testosterone TRT HRT Doctor Near Me

Online statistics

Members online
2
Guests online
5
Total visitors
7

Latest posts

bodybuilder test discounted labs
Top